

CURRICULUM VITAE

NAME: Kenneth D. Tew **DATE:**

PLACE OF BIRTH: Dumbarton, Scotland. Citizenship: US and UK.

Home address: 1833 Shell Ring Circle, Mt. Pleasant, SC 29466

Work address: Dept. of Cell and Molecular Pharmacology and Experimental Therapeutics Medical University of South Carolina, 173 Ashley Avenue, MSC505, Charleston, SC 29425.

Phone: 843-792-2514 (w) 843-971-0355 (h); FAX 843-792-2475; 843-991-3914 (c)

e-mail: tewk@musc.edu



MUSC Pharmacology home web page: <http://www2.musc.edu/pharm/index.html>

Scholarship:

A. DEGREES:

University of Wales, Swansea	1970-1973
B.Sc. , Microbiology/Genetics	
University of London, Institute for Cancer Research (Chester Beatty Cancer Research Institute), Ph.D. , Biochemical Pharmacology	1973-1976
University of London, D.Sc. , Faculty of Science.	1995

B. TRAINING:

Ph.D., Biophysics Department, Institute of Cancer Research, London.	1973-1976
Postdoctoral Research in Drug Combination Therapy, Radiopharmacology Department, Royal Marsden Hospital, Institute of Cancer Research, London.	1976-1977
Research Associate, Departments of Medicine and Biochemistry, Georgetown University School of Medicine, Washington, D.C.	1977-1979

C. APPOINTMENTS:

Instructor, Department of Medicine/ Biochemistry, Georgetown University School of Medicine, Washington, D.C.	1979-1980
Assistant Professor of Medicine/Biochemistry, Medicine/ Pharmacology.	1980-1984
Georgetown University Schools of Medicine and Dentistry, Washington, D.C.	1984-1985
Head Basic Pharmacology Program, Lombardi Cancer Center.	1982-1985

Member, Chairman of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA and Adjunct Associate Professor of Pharmacology, University of Pennsylvania.	1985-1990
Senior Member, Chairman of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA.	1990-2004
Adjunct Professor of Pharmacology, Univ. of Pennsylvania.	1992-2004
G. Willing Pepper Chair in Cancer Research.	1999-2004
Professor and Chairman, Dept of Molecular & Cellular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, S.C.	2004-
John C. West Chair in Cancer Research	2004-

Leadership and Administrative:

D. PEER-REVIEW COMMITTEES:

Scientific Advisory Committee Damon Runyon-Walter Winchell Cancer Fund, 1982; for VA Hospital Grant Review Process, 1985-; for NSF, 1986-; for MRC Canada, 1988-; Experimental Therapeutics II Study Section, 1986; (AHR-B1) SBIR Study Section, 1986, 1993 and 1995, ad hoc Chairman, 1994-97; NIH Clinical Sciences Fellowship Study Section, 1989; NIH Clinical Sciences Subcommittee 3 Study Section, 1989-; Chairman, Terry Fox Programme Project Review Team, Canada, 1991-1992; Ad hoc reviewer for MRC, U.K., 1991; Dutch Cancer Society, 1991-; Ad hoc SPORE grant review Prostate Cancer, 1993; Ad hoc Army Breast Cancer Review Panel, 1993; Ad hoc member of Experimental Therapeutics I Study Section 1986-1988, Permanent Member 1988-1993, Chairman 1990-1993; NCI, NIH Program Project Review Committees, 1985-, Parent Committee 1994-1998 and 2004-present, Chairman 1997; National Cooperative Drug Discovery Program, NCI, 1991, 1996 (Chairman); RAID review committee NCI, 2001-; DOD Breast Cancer Research Program, 1993, 1998, Chairman 1999-2002, Programmatic Integration Committee, 2005-present; Cancer Research Foundation of America, 1998-present; Melanoma Research Foundation ad hoc, 2004-present; Centers for Medical Countermeasures Against Radiation 2005; NIEHS ONES award review committee, 2006. External reviewer for the Dutch Cancer Society; the MRC, U.K.; the CRC, U.K.; The Wellcome Trust, U.K; Italian Association for Cancer Research (AIRC) 2007-. Linnaeus Foundation, Sweden 2008-. United Arab Emirates Research Foundation 2008-. AAAS Research Competitiveness Program: King Abdulaziz City for Science and Technology (KACST), 2009-. NCI DMP study section, 2009-. Subcommittee A, Cancer Centers of the NCI Review Panel, 2009-2113.

E. SCIENTIFIC ADVISORY BOARDS:

Academic: only those presently active are listed.

Arizona Cancer Center, SPORE in GI Malignancy (PI, Gene Gerner) PI2007-
 West Virginia University System, INBRE Program (PI, Gary Rankin) 2007-
 MD Anderson Drug Discovery Program (PI, Garth Powis) 2006-
 Pittsburgh Drug Discovery Institute (PI, John Lazo) 2006-

Industry:

Codon Pharmaceuticals, (Bethesda, MD.), 1995-1997.
US Bioscience (Conshohocken, PA.) 1987-1998.
Terrapin Technologies, Inc. - now Telik Inc., (San Francisco, CA.), 1991-2003.
Terrapharm Ventures, (Houston, Texas) 2004-2005.
Active Pass Inc., (Vancouver, B.C.) 2000-
Novelos Inc., (Waltham MA.) Chairman, Scientific Advisory Board, 2003-

F. EDITORIAL BOARDS

Previous:

- Pharmacology and Therapeutics, Associate Editor, 1987-1997.
- Cellular Pharmacology, Editor for the Americas, 1990-1997.
- Molecular Pharmacology, Editorial Board, 1991-1992; Associate Editor for Cancer Drugs, 1993-1995.
- American Journal of Pharmacogenomics, 2000-2006.
- American Journal of Cancer, Adis International Publishers, 2005-2007.

Ongoing:

- Cancer Research, Associate Editor: 1993-2007. Senior Editor in the Experimental Therapeutics, Molecular Targets, and Chemical Biology Section 2007-2009.
- Journal of Pharmacology & Experimental Therapeutics, 1999-2004, Associate Editor, 2004-present
- Drug Resistance Updates (publisher: Churchill Livingstone Intl.), 1997-present.
- Biochemical Pharmacology, 2002-present.
- Biomedicine & Pharmacotherapy, Editor in Chief: 2002-present.
- In Vivo, 2003-present.
- xPharm on-line drug information site, Elsevier Science Inc., New York, Editor 2005-present.
- Current Cancer Therapy Reviews, Bentham Science Publishers, 2005-present.
- Molecular Diagnosis and Therapy, 2006-present.
- Drug Design, Development and Therapy, DOVE Medical Press, 2007-present.
- The Open Cancer Journal, Bentham Science Publishers, 2007- present.

G. MISCELLANEOUS

- Co-chairman of the IX Bristol-Myers Cancer Symposium, Washington, DC, 1986.
- Gordon Research Conference on Chemotherapy of Clinical and Experimental Cancer: Vice-chairman 1988, Chairman, 1989.
- NASA/ACS Subcommittee Space Station Pharmacodynamics Study Group, 1988.
- Visiting Scholar, National Cancer Research Institute, Tokyo, Japan, December 1988 - March 1989.
- Second annual Harriet Tishchler Memorial Lecture, Harvard University, 1989.
- Program Committee (Experimental Therapeutics) for 1990, 1994, 1998, 1999 AACR Meetings.
- Chairman, Teller Committee AACR, 1992. Cain Memorial Award Committee of the AACR, 1993, Chairman 1994. Membership Committee, 1995. AACR fellowship review committee, 2002, 2003.
- American Cancer Society Scientific Research Award, 2003.

- Symposium Director: Cancer Drug Discovery and Development. HCC Spring Symposium 2007.
- President, Association of Medical School Pharmacology Chairs, 2007-2009.
- Elected Fellow, American Association for the Advancement of Science (AAAS), 2007.
- Chairman elect: Drug Discovery Development & Regulatory Affairs, ASPET 2011- 2013.

H. PROFESSIONAL SOCIETIES:

- American Society of Pharmacology and Experimental Therapeutics 1983-
- American Association for the Advancement of Science 1981-
- American Association of Cancer Research 1979-
- American Society for Cell Biology 1979-
- International Society for the Study of Xenobiotics 1996-

Academic/Industry grant support:

I. MAJOR RESEARCH INTERESTS:

- Anticancer drug discovery/development and drug target identification.
- Mechanisms of redox stress response.
- Glutathione metabolism.
- Mechanisms of drug resistance.

J. PRESENT, PENDING AND PAST PEER-REVIEWED RESEARCH SUPPORT:

(Current support in blue font; pending support in red; past support in black).

Direct costs awarded as Principal Investigator (Co-investigator support not listed)

PRESENT

NCI RO1 CA85660 Glutathione S-transferases in drug and stress response.	\$1,250,000: 04/2000-2005 \$1,250,000: 04/2005-2010
NIH R41CA117259 Preclinical development of a glutathione based cancer drug.	\$150,247: 09/2007-09/2009
Novelos Therapeutics Inc. Pharmacology of NOV-002	\$100,000: 9/2005-2006 \$125,000: 9/2006-2007 \$164,000: 9/2007-2008 \$210,650: 9/2008-2009 \$110,000: 9/2009-2010
NIH/NRSA T32 CA119945 Training in Cancer Therapeutics	\$165,622: 7/2006-6/2007 \$1,292,648: 7/2006-2011
NIH 1F32CA117749 (post-doctoral fellow: Jody Mack) Defining the Cellular and Physiological Role of ABCA2	\$48,796: 8/2006-7/2007 \$151,272: 08/2006-07/2009
South Carolina Center of Economic Excellence	yield varies on annual basis

Center for Cancer Research

P30 Cancer Center Support Grant

salary support as DCT leader
7/2009-7/2011

PENDING

NIH/NRRC P20RR024485
South Carolina COBRE in Oxidants, Redox Balance
and Stress Signaling

\$1,860,288: 6/2010-6/2011
\$7,779,952: 6/2010-6/2015

NIH/NCI CA140555-01 Interrogation of, and intervention
in the S-glutathionylation cycle

\$1,250,000: 2/2010-2/2015

NCI RO1 CA85660
Glutathione S-transferases in drug and stress response.

\$1,250,000: 04/2010-2015

PAST

NCI R01 formerly CA 28806, CA 43830-07,
Intranuclear Reactions and Drug Resistance

\$169,851: 12/80-11/83
\$196,823: 12/83-03/87
\$641,109: 04/87-03/92

NCI RO1 formerly CA 39373, CA 43783,
Estramustine as an Antimicrotubule Agent
in the Prostate.

\$198,174: 11/85-11/88
\$603,302: 03/89-02/94

1 R35 CA53893, Outstanding Investigator Grant,
Alkylating Agents and Drug Resistance
Supplement 1997.
Supplement 1998-2000.

\$4,061,874: 05/93- 04/2000

\$15,000

\$65,984

NCI RO1 CA83778
Determinants of Estramustine Resistance and Response.

\$1,271,342: 04/2000-2/2007

NCI P50 CA83638 Ovarian cancer SPORE
project 5 :-The role of DNA dependent protein
kinase in ovarian cancer drug resistance.

\$300,000: 10/1999-2004

NCI CA 50202, Gordon Research Conference

\$ 16,100: 6/1989

Bristol Myers: (peer reviewed)
Glutathione S-Transferases and Drug Resistance

\$500,000: 7/1988-1993

Sterling Winthrop

\$400,000: 1/1993-1995

Terrapin (since 1998, Telik) Technologies, San Francisco

\$188,000: 10/1992-1994

\$127,500: 7/1996-1998

\$127,500: 8/1998-1999

	\$200,000: 6/2001-2003
Helsingborg Research Foundation, Sweden	\$ 121,000: 3/1983-1988
Mechanism of Action of Steroid/Alkylating Agent Complexes	\$ 112,000: 7/1988-1992
	\$ 164,000: 11/1992-1996
Wyeth-Ayerst	\$ 36,000: contract, 1999
US Bioscience	\$ 200,000: 12/1998-2000
ActivePass Pharmaceuticals, Vancouver	\$ 200,000: 12/2000-2002
Support through FCCC Core Grant:	
Director of Imaging Core Facility	\$ 180,000: 7/00-2005
Head of Drug & Radiation Resistance Group	\$ 75,000: 7/00-2005
Postdoctoral Training Grant in Cancer	
Pharmacology Fox Chase Cancer Ctr.(T32 CA75266)	\$620,796: 4/98-2003.

K. SUMMARY OF TEACHING ACTIVITIES:

Georgetown University Schools of Medicine and Dentistry (1979-1985):

Medical school:

(1980-1985) General Biochemistry - Amino Acid Metabolism

Graduate school:

(1980-1985) Molecular Biology - DNA Repair, Carcinogenesis, Nuclear Structure, Chemical Reactions, Detoxification, Laboratory Safety

ICS Course - Epidemiology and Carcinogenesis

Pharmacology mini-course - Molecular Pharmacology of Anticancer Drugs

Georgetown University School of Medicine Health Careers Program (1979-1983)

(Pre Medical and Dental Students):

Lipid Biochemistry

Amino Acid Metabolism

Introduction to Cancer Research

University of Pennsylvania

Medical School

(1986-1992) Antibiotics: Sulfonamides, Tetracyclines, Cephalosporins and Penicillins

Graduate School

(1986-1999) Biology of Cancer

(1988-1998) Drug Metabolism I & II

(1990-1994) Drug Metabolism Courses for Pharmaceutical Industries

(1999-2004) Anticancer drug resistance

MUSC

Medical school

(2006-present)

Evolution and medicine

Pharmacogenetics

Graduate school:

(2005-present)

Redox chemistry and drug action

Drug resistance

Pharmacogenetics

Drug discovery/development and the FDA

External Ph.D. examiner: - University of Aston, Birmingham, England (1982), University of Uppsala, Sweden (1993), Dartmouth Medical School (1997), University of Wageningen, Holland (1998).

Advisor to graduate students,

Bruce Moy, Georgetown University, (Biochemistry graduate 1985).

Amy Buller (Pharmacology), 1984-1986, Georgetown University.

Miechelle O'Brien, University of Pennsylvania (Pharmacology graduate, 1999).

Zhanna Lipatova, M.S. Moscow State University, (Molecular biology graduate, 2001)

Cameron McIlwain, MUSC, 2005-2008

Scholarly published material:

L. PATENTS:

1. **Tew, K.D.**, Ronai, Z. and Adler, V.: Methods to identify compounds affecting the regulation of Jun Kinase by glutathione S-transferase π . Patent application #60/122,147.
2. **Tew, K.D.**, Vulevic, B. and Chen, Z. Nucleic acid encoding human ABC transporter 2 (hABC2) and methods of use thereof. Patent #60/154,839.
3. Chen, Z., Shen, H. and **Tew, K.D.** "Methods For Gene Expression Profiling." Patent # 60, 289,167.
4. Pending: **Tew, K.D.**, Townsend, D.M., Smith, C.H. "Small molecule inhibitors of Protein Disulfide Isomerase." MUSC-FRD File #: PO928.
5. Pending: **Tew, K.D.**, Townsend, D.M. "Plasma protein biomarkers for exposure to ROS/RNS or drugs that cause ROS/RNS." MUSC-FRD File #: PO927.

M. PUBLICATIONS:

Peer reviewed:

1. Taylor, D., **Tew, K.D.** and Jones, J. Effects of cis-dichlorodiammine platinum (II) on DNA synthesis in kidney and other tissues of normal and tumor-bearing rats. Eur. J. Cancer 12:249-254, 1976.
2. Houghton, P., **Tew, K.D.** and Taylor, D. Some studies on the distribution and effects of cyclophosphamide (NSC-26271) in normal and neoplastic tissues. Cancer Treat. Rep. 60:459-464, 1976.
3. **Tew, K.D.** and Taylor, D. The effect of methotrexate on the uptake of *de novo* and *salvage* precursors into the DNA of rat tumors and normal tissues. Eur. J. Cancer 13:279-289, 1977.
4. **Tew, K.D.** and Taylor, D. The relationship of thymidine metabolism to the use of fractional incorporation as a measure of DNA synthesis and tissue proliferation. Eur. J. Cancer 14:153-168, 1978.
5. **Tew, K.D.** and Taylor, D. Studies with cyclophosphamide labeled with phosphorus-32: Nucleic acid alkylation and its effect on DNA synthesis in rat tumor and normal tissues. J.N.C.I. 49:1413-1419, 1978.
6. **Tew, K.D.** and Taylor, D. Tissue distribution and nucleic acid binding of chlorambucil ^3H in tumor-bearing rats. Experientia 34/9:1215-1216, 1978.

7. **Tew, K.D.**, Sudhakar, S., Schein, P. and Smulson, M. Binding of chlorozotocin and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea to chromatin and nucleosomal fractions of HeLa cells. *Cancer Res.* 38:3371-3378, 1978.
8. Pinsky, S., **Tew, K.D.**, Smulson, M.E. and Woolley, P.V. Modification of L1210 cell nuclear proteins by methyl-1-nitrosourea and 1-methyl-3-nitro-1-nitrosoguanidine. *Cancer Res.* 39:923-928, 1979.
9. Sudhakar, S., **Tew, K.D.** and Smulson, M.E. Effect of 1-methyl-3-nitro-1-nitrosourea on poly (adenosine diphosphate-ribose) polymerase activity at the nucleosome level. *Cancer Res.* 39:1405-1410, 1979.
10. Sudhakar, S., **Tew, K.D.**, Schein, P.S., Woolley, P.V. and Smulson, M.E. Nitrosourea interaction with chromatin and effect on poly (adenosine diphosphate-ribose) polymerase activity. *Cancer Res.* 39:1411-1417, 1979.
11. **Tew, K.D.** and Taylor, D.M. Cyclophosphamide and cis-dichlorodiammine platinum (II): Non-empiric scheduling to spare dose-limiting tissues in the rat. *Cancer Chemother. Pharmacol.* 4:103-109, 1980.
12. Jump, D.B., Sudhakar, S., **Tew, K.D.** and Smulson, M.E. Probes to study the effect of methyl nitrosourea on poly ADP-ribosylation and chromatin structure at the subunit level. *Chem. Biol. Interact.* 30/1:35-52, 1980.
13. **Tew, K.D.**, Schein, P.S., Lindner, D., Wang, A.L. and Smulson, M.E. Influence of hydrocortisone on the binding of nitrosoureas to nuclear chromatin structure. *Cancer Res.* 40:3697-3703, 1980.
14. **Tew, K.D.**, Wang, A.L., Lindner, D. and Schein, P.S. Enhancement of nitrosourea cytotoxicity *in vitro* using hydrocortisone. *Biochem. Pharmacol. Commun.* 31:1179-1180, 1982.
15. Green, D., **Tew, K.D.**, Hisamatsu, T. and Schein, P.S. Correlation of nitrosourea murine bone marrow toxicity with deoxyribonucleic acid alkylation and chromatin binding sites. *Biochem. Pharmacol.* 31:1671-1679, 1982.
16. **Tew, K.D.**, and Wang, A.L. Selective cytotoxicity of haloethylnitrosoureas in a carcinoma cell line resistant to bifunctional nitrogen mustards. *Mol. Pharmacol.* 21:729-738, 1982.
17. Ahlgren, J.D., Green, D.C., **Tew, K.D.** and Schein, P.S. Repair of DNA alkylation in L1210 leukemia and murine bone marrow by three chloroethylnitrosoureas. *Cancer Res.* 42:2605-2608, 1982.
18. **Tew, K.D.** Comparative cytotoxic properties of ifosfamide and cyclophosphamide in a rat solid tumor and normal tissues. *Sem. Oncol.* 4:24-27, 1982.
19. Wang, A.L., Schein, P.S. and **Tew, K.D.** Importance of phospholipids to nitrosourea interactions with the nuclear envelope and associated nucleic acids. *Oncology* 40:367-371, 1983.
20. **Tew, K.D.**, Wang, A.L. and Schein, P.S. Alkylating agent interactions with the nuclear matrix. *Biochem. Pharmacol.* 32:3509-3516, 1983.
21. **Tew, K.D.**, Erickson, L.C., White, G., Wang, A.L., Schein, P.S. and Asp, B. Cytotoxicity of estramustine, a steroid-nitrogen mustard derivative, through non-DNA targets. *Mol. Pharmacol.* 24:324-328, 1983.
22. **Tew, K.D.**, Moy, B.C. and Hartley-Asp, B. Acquired drug resistance is accompanied by modification in the karyotype and nuclear matrix of a rat carcinoma cell line. *Exptl. Cell Res.* 149:443-450, 1983.
23. Byrne, P.J., **Tew, K.D.**, Jemionek, J., MacVittie, T., Crickson, L. and Schein, P. Cellular and molecular mechanisms of the bone marrow sparing effects of the glucose chloroethylnitrosourea chlorozotocin. *Blood* 63:759-767, 1984.
24. **Tew, K.D.** and Hartley-Asp, B. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. *Urology* 23:28-33, 1984.
25. Farhi, J.J., Bennoun, M., Tapiero, H., Wang, A.L. and **Tew, K.D.** Biochemical and cytotoxic properties of the isomeric forms of bis (2-chloroethyl)-N-nitroso-N-carbamoyl cystamine. *Biochem. Pharmacol.* 33:2575-2580, 1984.

26. Lown, J.W., Koganty, R.R., **Tew, K.D.**, Oiry, J. and Imbach, J.L. Mechanism of action of 2-haloethylnitrosoureas on deoxyribonucleic acid. Pathways of aqueous decomposition and pharmacological characteristics of new anticancer disulfide linked nitrosoureas. *Biochem. Pharmacol.* 34:1015-1024, 1985.
27. **Tew, K.D.**, Kyle, G., Johnson, A. and Wang, A.L. Carbamoylation of glutathione reductase and changes in cellular and chromosome morphology in a rat cell line resistant to nitrogen mustards but collaterally sensitive to nitrosoureas. *Cancer Res.* 45:2326-2333, 1985.
28. Moy, B.C. and **Tew, K.D.** Poly(adenosine diphosphate-ribosylation) of nuclear matrix in alkylating agent resistance and sensitive cell lines. *Chem. Biol. Interact.* 54:209-222, 1985.
29. Stearns, M.E., Jenkins, D.P. and **Tew, K.D.** Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets. *Proc. Natl. Acad. Sci. USA* 82:8483-8487, 1985.
30. Stearns, M.E. and **Tew, K.D.** Antimicrotubule effects of estramustine, an antiprostic tumor drug. *Cancer Res.* 45:3891-3897, 1985.
31. Vu, V.T., Moy, B.C., Schein, P.S. and **Tew, K.D.** Enhanced nitrosourea cytotoxicity in cell culture by sodium butyrate. *Oncology* 42:317-321, 1985.
32. Wang, A.L. and **Tew, K.D.** Increased glutathione-S-transferase activity in a cell line with acquired resistance to nitrogen mustards. *Cancer Treat. Rep.* 69:677-682, 1985.
33. Dean, S.W., **Tew, K.D.**, Clark, A.E. and Schein, P.S. DNA repeat length in chromatin from murine bone marrow and L1210 leukemia cells. *Brit. J. Cancer* 52:377-382, 1985.
34. Dean, S.W., Johnson, A. and **Tew, K.D.** A comparative analysis of drug-induced DNA effects in a nitrogen mustard resistant cell line expressing sensitivity to nitrosoureas. *Biochem. Pharmacol.* 35:1171-1176, 1986.
35. **Tew, K.D.**, Woodworth, A. and Stearns, M.E. Relationship of glutathione depletion and inhibition of glutathione S-transferase activity to the antimetabolic properties of estramustine. *Cancer Treat. Rep.* 70:715-720, 1986.
36. Moy, B.C. and **Tew, K.D.** Differences in the nuclear matrix phosphoproteins of a wild-type and nitrogen mustard resistant rat breast carcinoma cell line. *Cancer Res.* 46:4672-4676, 1986.
37. Dean, S.W., Gibson, N.W. and **Tew, K.D.** Selection of nitrogen mustard resistance in a rat tumor cell line results in loss of guanine-06-alkyl transferase activity. *Mol. Pharmacol.* 30:77-80, 1986.
38. Hartley-Asp, B., Billstrom, A. and **Tew, K.D.** C-Banding of two Walker 256 rat carcinoma cell lines sensitive and resistant to bifunctional mustards. *Anticancer Res.* 7:209-214, 1987.
39. Buller, A.L., Clapper, M.L. and **Tew, K.D.** Glutathione-S-transferases in nitrogen mustard-resistant and -sensitive cell lines. *Mol. Pharmacol.* 31:575-578, 1987.
40. **Tew, K.D.**, Dean, S.W. and Gibson, N.W. The effect of a novel taurine nitrosourea, 1-(2-chloroethyl)-3-[2-(diamehtylaminosulfonyl)ethyl]-1-nitrosourea (TCNU) on cytotoxicity, DNA crosslinking and glutathione reductase in lung carcinoma cell lines. *Cancer Chemother. Pharmacol.* 19:291-295, 1987.
41. **Tew, K.D.** and Stearns, M.E. Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine. *Urol. Res.* 15:155-160, 1987.
42. **Tew, K.D.**, Clapper, M.L., Greenberg, R.E., Weese, J.L., Hoffman, S.J. and Smith, T.M. Glutathione S-transferases in human prostate. *Biochim. Biophys. Acta* 926:8-15, 1987.
43. Stearns, M.E. and **Tew, K.D.** Estramustine binds MAP-2 to inhibit microtubule assembly *in vitro*. *J. Cell Sci.* 89:331-342, 1988.
44. Wang, M., **Tew, K.D.** and Stearns, M.E. Immunofluorescent studies of the anti-microtubule effects of the anticancer drug estramustine. *Anticancer Res.* 7:1165-1172, 1987.
45. **Tew, K.D.**, Bomber, A.M. and Hoffman, S.J. Ethacrynic acid and piriprost as enhancers of cytotoxicity

- in drug resistant and sensitive cell lines. *Cancer Res.* 48:3622-3625, 1988.
46. Stearns, M., Wang, M., Tew, K. D. and Binder, L. I. Estramustine binds a MAP-1-like protein to inhibit microtubule assembly *in vitro* and disrupt microtubule organization in DU145 cells. *J. Cell Biol.* 107:2647-2656, 1988.
 47. LaCreta, F.P., Olszewski, J.J. and **Tew, K.D.** Purification of glutathione S-transferases from rat liver and Walker 256 mammary carcinoma cells by high-performance liquid chromatography and a glutathione affinity column. *J. Chromatog.* 434:83-93, 1988.
 48. Clapper, M.L. and **Tew, K.D.** Identification of a glutathione S-transferase associated with microsomes of tumor cells resistant to nitrogen mustards. *Biochem. Pharmacol.* 38:1915-1921, 1989.
 49. Tapiero, H., Ming-Biao, Y., Catalin, J., Paraire, M., Deloffre, P., Rustum, Y., Bizzari, J.-P. and **Tew, K. D.** Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl-1-(3-[2-chloroethyl]-3-nitrosoureido) ethylphosphonate -S10036. *Anticancer Res.* 9:1438-1441, 1989.
 50. Nakagawa, K., Saijo, N., Tsuchida, S., Sakai, M., Tsunokawa, M., Yokota, J., Murumatsu, M., Sato, K., Terada, M. and **Tew, K. D.** Glutathione S-transferase π as a determinant of drug resistance in transfectant cells lines. *J. Biol. Chem.* 265:4296-4301, 1990.
 51. Schisselbauer, J., Silber, R., Papadopoulous, E., LaCreta, F.P. and **Tew, K.D.** Characterization of lymphocyte glutathione S-transferase isozymes in chronic lymphocytic leukemia (CLL). *Cancer Res.* 50:3569-3573, 1990.
 52. Schisselbauer, J., Cresciamanno, M., D'Alessandro, N., Clapper, M.L., Tapiero, H. and **Tew, K.D.** Glutathione, glutathione S-transferases and related redox enzymes in adriamycin resistant cell lines with a multidrug resistant phenotype. *Cancer Commun.* 1:133-139, 1989.
 53. Clapper, M. L., Hoffman, S. J. and **Tew, K. D.** Sensitization of human colon xenografts to melphalan using an inhibitor of glutathione S-transferase. *J. Cell. Pharmacol.* 1:71-78, 1990.
 54. Fujiwara, Y., Sugimoto, Y., Kasahara, K., Bungo, M., Yamakido, M. **Tew, K.D.** and Saijo, N. Determinants of drug response in a cisplatin resistant human lung cancer cell line. *Jpn. J. Cancer Res.* 81:527-535, 1990.
 55. Ciaccio, P.J., **Tew, K.D.** and LaCreta, F.P. The spontaneous and glutathione S-transferase-mediated reaction of chlorambucil with glutathione. *Cancer Commun.* 2:279-286, 1990.
 56. Clapper, M.L., Hoffman, S.J. and **Tew, K.D.** Glutathione S-transferases in normal and malignant colon tissue. *Biochim. Biophys. Acta* 1096:209-216, 1991.
 57. Kuzmich, S., Vanderveer, L.A. and **Tew, K.D.** Evidence for a glycoconjugate form of glutathione S-transferase π . *Int. J. Peptide and Protein Res.* 37:565-571, 1991.
 58. Speicher, L.A., Sheridan, V.R., Godwin, A. and **Tew, K.D.** Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype. *Brit. J. Cancer* 64:267-273, 1991.
 59. Sheridan, V.R., Speicher, L.A. and **Tew, K.D.** The effects of estramustine on mitotic progression in DU145 human prostatic carcinoma cells. *Eur. J. Cell Biol.* 54:268-276, 1991.
 60. Morris, D., Speicher, L.A., Ruoho, A., **Tew, K.D.** and Seamon, K.B. Interaction of forskolin with the P-glycoprotein multidrug transporter. *Biochemistry* 30:8371-8379, 1991.
 61. Ciaccio, P.J., **Tew, K.D.** and LaCreta, F.P. Enzymatic conjugation of chlorambucil with glutathione is catalyzed by human glutathione S-transferases and inhibition by ethacrynic acid. *Biochem. Pharmacol.* 42: 1504-1507, 1991.
 62. Clapper, M.L., Hoffman, S.J., Carp, N., Watts, P., Seestaller, L.M., Weese, J.L. and **Tew, K.D.** Contribution of patient history to the GST activity of human lung, breast and colon tissue. *Carcinogenesis* 12:1957-1961, 1991.
 63. Ranganathan, S. and **Tew, K.D.** Immunohistochemical localization of glutathione S-transferases α, μ^{**} and π in normal and tumor tissue from human colon. *Carcinogenesis* 12:2383-2387, 1991.
 64. O'Dwyer, P.J., LaCreta, F., Nash, S., Tinsley, P.W., Schilder, R., **Tew, K.D.**, Panting, L., Litwin, S.,

- Comis, R.L. and Ozols, R.F. Phase I study of Thio-TEPA in combination with the glutathione transferase inhibitor ethacrynic acid. *Cancer Res.* 51:6059-6065, 1991.
65. Punzi, J.S., Duax, W.L., Strong, P., Griffin, J.F., Flocco, M., Zacharias, D., **Tew, K.D.** and Glusker, J.P. Molecular conformation of estramustine and two analogues. *Mol. Pharmacol.* 41:569-576, 1992.
 66. Schisselbauer, J.C., Hogan, W.M., Buetow, K.A. and **Tew, K.D.** Heterogeneity of glutathione S-transferase enzyme and gene expression in ovarian carcinoma. *Pharmacogenetics* 2:63-72, 1992.
 67. Kuzmich, S., Vanderveer, L.A., Walsh, E.S., LaCreta, F.P. and **Tew, K. D.** Increased levels of glutathione S-transferase π -transcript as a mechanism of resistance to ethacrynic acid. *Biochem. J.* 281:219-224, 1992.
 68. O'Dwyer, P.J., Hamilton, T.C., Young, R.C., LaCreta, F.P., Carp, N., **Tew, K.D.**, Padavic, K., Comis, R.L. and Ozols, R.F. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: Clinical and biochemical results. *J. Natl. Cancer Instit.* 84:264-267, 1992.
 69. Speicher, L.A., Barone, L. and **Tew, K.D.** Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. *Cancer Res.* 52:4433-4440, 1992.
 70. Hudes, G.R., Greenberg, R., Kriegel, R.L., Fox, S., Scher, R., Litwin, S., Watts, P., Speicher, L., **Tew, K.D.** and Comis, R. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer. *J. Clin. Oncol.* 10:1754-1761, 1992.
 71. Clapper, M.L., Kuzmich, S., Seestaller, L.M., Hardy, R.R., and **Tew, K.D.** Time course of glutathione S-transferase elevation in Walker mammary carcinoma cells following chlorambucil exposure. *Biochem. Pharmacol.* 45:683-690, 1993.
 72. Ranganathan, S. and **Tew, K.D.** Analysis of glyoxalase-1 from normal and tumor tissue from human colon. *Biochim. Biophys. Acta* 1182:311-316, 1993.
 73. Ciaccio, P.J., Stuart, J.E. and **Tew, K.D.** Overproduction of a 37.5 kD cytosolic protein structurally related to prostaglandin F synthase in ethacrynic acid resistant human colon cells. *Mol. Pharmacol.* 43:845-853, 1993.
 74. Ranganathan, S., Walsh, E.S., Godwin, A.K. and **Tew, K.D.** Cloning, sequencing and expression of human colon glyoxalase-I. *J. Biol. Chem.* 268:5661-5667, 1993.
 75. LaCreta, F.P., Brennan, J.M., Nash, S., Comis, R.L., **Tew, K.D.** and O'Dwyer, P.J. Pharmacokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. *J. Pharmacol. Exper. Ther.* 270:1186-1191, 1994.
 76. Speicher, L.A., Laing, N., Barone, L., Robbins, J.D., Seamon, K.B. and **Tew, K.D.** Interaction of estramustine photoaffinity analog with cytoskeletal proteins in prostate carcinoma cells. *Mol. Pharmacol.* 46:866-872, 1994.
 77. Speicher, L.A., Barone, L.R., Chapman, A.E., Hudes, G.R., Laing, N., Smith, C.D. and **Tew, K.D.** P-glycoprotein binding and modulation of the MDR phenotype by estramustine. *J.N.C.I.* 86:688-694, 1994.
 78. Ciaccio, P.J., Jaiswal, A.K. and **Tew, K.D.** Regulation of human dihydrodiol dehydrogenase by Michael acceptor xenobiotics. *J. Biol. Chem.* 269:15558-15562, 1994.
 79. Ciaccio, P.J. and **Tew, K.D.** cDNA and deduced amino acid sequences of a human colon dihydrodiol dehydrogenase. *Biochem. Biophys. Acta* 1186:129-132, 1994.
 80. Smith, C.D., Zilfou, J.T., Zhang, X., Hudes, G.R. and **Tew, K.D.** Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins. *Cancer* 75:2597-2604, 1995.
 81. Ranganathan, S., Walsh, E.S. and **Tew, K.D.** Glyoxalase-I in detoxification-studies using a glyoxalase-I transfectant cell line. *Biochem. J.*309:127-131, 1995.

82. Speicher, L.A., Barone, L. and **Tew, K.D.** Altered regulation of cytoskeletal elements in estramustine resistant cell lines. *Cell. Pharmacol.* 2:91-96, 1995.
83. Zacharias, D.E., Glusker, J.P., **Tew, K.D.** and Hartley-Asp, B. Comparison of estramustine with its dihydroxy analogue, estradiol 3-N-bis(2'-hydroxyethyl)carbamate. *Struct. Chem.* 6:371-376, 1995.
84. Shen, H., Ranganathan, S., Kuzmich, S. and **Tew, K.D.** Influence of ethacrynic acid on glutathione S-transferase π transcript and protein half-lives in human colon cancer cells. *Biochem. Pharmacol.* 50:233-238, 1995.
85. Ciaccio, P.J., Shen, H., Jaiswal, A.K., Lyttle, M.H. and **Tew, K.D.** Modulation of detoxification gene expression in human colon HT29 cells by glutathione S-transferase inhibitors. *Mol. Pharmacol.*, 48:639-647, 1995.
86. Morgan, A.S., Ciaccio, P.J., **Tew, K.D.** and Kauvar, L.M. Isozyme specific GST inhibitors potentiate drug sensitivity in cultured human tumor cell lines. *Cancer Chemother. Pharmacol.* 37:363-370, 1996.
87. Shen, H., Paul, S., Breuninger, L.M., Ciaccio, P.J., Laing, N.M., Helt, M., **Tew, K.D.** and Kruh, G.D. Cellular and *in vitro* transport of glutathione conjugates by MRP. *Biochemistry*, 35:5719-5725, 1996.
88. **Tew, K.D.**, Monks, A., Barone, L., Rosser, D., Akerman, G., Montali, J.A., Wheatley, J.B. and Schmidt, D. Glutathione associated enzymes in the human cell lines of the National Cancer Institute drug screening program. *Mol. Pharmacol.* 50:149-159, 1996.
89. Ranganathan, S., Dexter, D.W., Benetatos, C.A., Chapman, A.E., **Tew, K.D.** and Hudes, G.R. Increase of β_{III} and β_{IVa} tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. *Cancer Res.* 56:2584-2589, 1996.
90. Ciaccio, P.J., Shen, H., Kruh, G.D. and **Tew, K.D.** Effects of ethacrynic acid exposure on conjugation and MRP mediated efflux in human colon tumor cells. *Biochem. Biophys. Res. Commun.* 222:111-115, 1996.
91. Tapiero, H. and **Tew, K.D.** Increased glutathione expression in cells induced by *Crassostera gigas* extract. *Biomed. Pharmacother.* 50:149-153, 1996.
92. Ciaccio, P.J., Walsh, E.S. and **Tew, K.D.** Promoter analysis of a human dihydrodiol dehydrogenase. *Biochem. Biophys. Res. Commun.* 228:524-529, 1996.
93. Laing, N., Dahloff, B., Hartley-Asp, B., Ranganathan, S. and **Tew, K.D.** The interaction of estramustine with tubulin isotypes. *Biochemistry* 36:871-878, 1997.
94. Shen, H., Kruh, G.D. and **Tew, K.D.** Increased expression of DNA-dependent protein kinase confers resistance to adriamycin. *Biochim. Biophys. Acta*, 1381:131-138, 1998.
95. Sangrajrang, S., Denoulet, P., Laing, N.M., Tatoud, R., Millot, G., Calvo, F., **Tew, K.D.** and Fellous, A. Association of estramustine resistance in human prostate carcinoma cells with modified patterns of tubulin expression. *Biochem. Pharmacol.* 55:325-331, 1998.
96. Sangrajrang, S., Denoulet, P., Millot, G., Tatoud, R., Podgorniak, M-P., **Tew, K.D.**, Calvo, F. and Fellous, A. Estramustine correlates with tau overexpression in human prostatic carcinoma cells. *Int. J. Cancer* 77:626-631, 1998.
97. Morgan, A.S., Sanderson, P.E., Borch, R.F., **Tew, K.D.**, Niitsu, Y., Takayama, T., Von Hoff, D.D., Izbicka, E., Mangold, G., Paul, C., Broberg, U., Mannervik, B., Henner, D.W. and Kauvar, L.M. Tumor efficacy and bone marrow sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. *Cancer Res.* 58:2568-2575, 1998.
98. Laing, N.M., Belinsky, M.G., Kruh, G.D., Bell, D.W., Boyd, J., Barone, L.B. and **Tew, K.D.** Amplification of the *ABC2* transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. *Cancer Res. (Adv. in Brief)* 58:1332-1337, 1998.
99. Gaté, L., Schultz, M., Walsh, E., Dhalluin, S., Nguyen Ba, G., Tapiero, H. and **Tew, K.D.** Impact of

- dietary supplement of *Crassostrea gigas* extract (JCOE) on glutathione levels and glutathione S-transferase activity in rat tissues. *In Vivo* 12:299-304, 1998.
100. Tapiero, H., Gaté, L., Dhalluin, S., Nguyen Ba, G., Soupramanien, V., Kouyate, J. and **Tew, K.D.** The antioxidant effects of *Crassostrea gigas* extract (JCOE) in human volunteers. *In Vivo* 12:305-310, 1998.
 101. Shen, H., Schultz, M.P. and **Tew, K.D.** Glutathione conjugate interactions with DNA-dependent protein kinase. *J. Pharmacol. Exper. Ther.* 290:1101-1106, 1999.
 102. Adler, V., Yin Z., Fuchs, S.Y., Benezra, M., Rosario, L., **Tew, K.D.**, Pincus, M.R., Sardana, M., Henderson, C.J., Wolf, C.R., Davis, R. and Ronai, Z. Regulation of JNK signaling by GSTp. *EMBO J.* 18:1321-1334, 1999.
 103. O'Brien, M.L., Vulevic, B., Freer, S., Boyd, J., Shen, H. and **Tew, K.D.** Glutathione peptidomimetic drug modulator of the multidrug resistance associated protein. *J. Pharmacol. Exper. Ther.* 291:1348-1355, 1999.
 104. Ranganathan, S., Ciaccio, P.J., Walsh, E. and **Tew, K.D.** Genomic sequence of Glyoxalase I: analysis of promoter activity and its regulation. *Gene* 240:149-155, 1999.
 105. Frei, E. III, Ara, G., Teicher, B., Bunnell, B., Richardson, P., Wheeler, C., **Tew, K.D.** and Elias, A. Double high dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. *Cancer Chemother Pharmacol.* 45:239-246, 2000.
 106. O'Brien, M., Kruh, G.D. and **Tew, K.D.** The influence of co-ordinate overexpression of glutathione phase II detoxification gene products on drug resistance. *J. Pharmacol. Exper. Ther.* 294:480-487, 2000.
 107. Rosario, L.A., O'Brien, M., Henderson, C., Wolf, C.R. and **Tew, K.D.** Cellular response to a glutathione S-transferase activated prodrug. *Mol. Pharmacol.*, 58:167-174, 2000.
 108. Yin, Z., Ivanov, V., Habelhah, H., **Tew, K.D.** and Ronai, Z. Glutathione S-transferase p elicits protection against hydrogen peroxide-induced cell death via coordinated regulation of stress kinases. *Cancer Res. (Adv. In Brief)* 60:4053-4057, 2000.
 109. Vulevic, B., Chen, Z., Davis, W., Walsh, E. S., Belinsky, M. G. and **Tew, K.D.** Cloning and characterization of human adenosine 5'-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). *Cancer Res.* 61:3339-3347, 2001.
 110. Shen, H., Chen, Z., Zilfou, J. T., Hopper E., Murphy, M.E. and **Tew, K.D.** Binding of the aminothiols WR-1065 to transcription factors influences the cellular response to anticancer drugs. *J. Pharmacol. Exper. Ther.* 297:1067-1073, 2001.
 111. Chen, Z.J., Shen, H. and **Tew, K.D.** Gene expression profiling using a novel method: amplified differential gene expression (ADGE). *Nucleic Acids Res.*, 29:e46-e51, 2001.
 112. Wang, T., Arifoglu, P., Ronai, Z. and **Tew, K.D.** Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun NH₂ terminal kinase (JNK1) signaling through interaction with carboxyl terminal. *J. Biol. Chem.* 274:20999-21003, 2001.
 113. Ruscoe, J., Rosario, L., Henderson, C., Wolf, C.R., Adler, V., Ronai, Z. and **Tew, K.D.** Pharmacologic or genetic manipulation of glutathione S-transferase P1-1(GST*) influences cell proliferation pathways. *J. Pharmacol. Exper. Ther.* 298:339-345, 2001.
 114. Gaté, L., Vauthier, C., Couvreur, P., **Tew, K.D.**, Tapiero, H. Glutathione-loaded poly(isobutylcyanoacrylate) nanoparticles and liposomes: comparative effects in murine erythroleukaemia and macrophage-like cells. *Stp Pharma Sciences* 11:355-361, 2001.
 115. Townsend, D. M., Shen, H., Staros, A. L. and **Tew, K.D.** Efficacy of a glutathione S-transferase activated prodrug in platinum resistant ovarian cancer cells. *Molecular Cancer Therapeutics*, 1: 1089-1095, 2002.
 116. Chen, Z., Gaté, L., Davis, W., Ile, K.E. and **Tew, K.D.** Gene Profiling Improved by the Combination of

- DNA Microarray and Amplified Differential Gene Expression (ADGE). *BMC Genomics*, 4: 28, 2003. <http://www.biomedcentral.com/1471-2164/4/28>
117. Davis, W., Chen, Z. J., Ile, K.E. and **Tew, K.D.** Sp-family and EGR-1 transcription factors regulate expression of the human ABCA2 promoter. *Nucleic Acids Res.*, 31: 1097-1107, 2003.
 118. Gaté, L., Lunk, A. and **Tew, K.D.** Resistance to phorbol 12-myristate 13-acetate-induced cell growth arrest in an HL60 cell line chronically exposed to a glutathione S-transferase π inhibitor. *Biochemical Pharmacology*, 65: 1611-1622.
 119. Efferth T., Sauerbrey A., Olbrich A., Gebhart E., Rauch, P., Weber, H.O., Hengstler J.G., Halatsch M., Volm M, **Tew, K.D.**, Ross D.D. and Funk J. Molecular modes of action of Artesunate in tumor cell lines. *Molecular Pharmacology* 64: 382-394, 2003.
 120. Gaté, L., Majumdar, R.S., Lunk, A. and **Tew, K.D.** Increased myeloproliferation in glutathione S-transferase π deficient mice is associated with a deregulation of c-Jun-NH₂-Terminal Kinase and Janus Kinase/Signal Transducer and Activator of Transcription Pathways. *J. Biol. Chem.* 279: 8608-8616, 2004.
 121. Findlay, V.J., Townsend, D.M., Saavedra, J.E., Buzard, G.S., Citro, M.L., Keefer, L.K., Ji, X. and **Tew, K.D.** Tumor cell response to a novel glutathione S-transferase activated nitric oxide releasing prodrug. *Molecular Pharmacology* 65: 1070-1079, 2004.
 122. Ile K.E., Davis W. Jr. and **Tew, K.D.** Identification of novel first exon of human ABCA2 transporter gene encodes a unique N-terminus. *BBA*, 1678: 22-32, 2004.
 123. Davis W. Jr., Boyd J.T., Ile K.E. and **Tew, K.D.** Adenosine 5'-triphosphate-binding Cassette, Sub-family A, transporter 2 (ABCA2) is a sterol-responsive gene with a functional role in low-density lipoprotein derived cholesterol homeostasis. *BBA*, 1683: 89-100, 2004.
 124. Chen, Z.J., Vulevic, B., Ile, K.E., Soulika, A., Davis W., Trojanowski, J.Q. and **Tew, K.D.** Association of ABCA2 Expression With Determinants of Alzheimer's Disease. *FASEB J.*, 18:1129-1131, 2004.
 125. Gaté, L., Majumdar, R.S. Lunk, A. and **Tew, K.D.** Influence of Glutathione S-transferase π and p53 expression on tumor frequency and spectrum in mice. *International Journal of Cancer*, 113: 29-35, 2005.
 126. Boonstra,R., Timmer-Bosscha, H., van Echten-Arends, J., van der Kolk, D., van den Berg, A., de Jong, B., **Tew, K.D.**, Poppema, S. and de Vries,E.G.E. Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. *British Journal of Cancer*, 90: 2411-2417, 2004.
 127. Tucker, J.M., Lipatova Z., Beljanski, V., Townsend, D. M. and **Tew, K.D.** Evaluation of lipophilins as determinants of tumor cell response to estramustine. *J. Pharmacol. Exper. Ther.* 315: 1158-1162, 2005.
 128. Beljanski, V., Soulika, A , Tucker, J.M., Townsend, D.M., Davis W. Jr., and **Tew, K.D.** Characterization of the ATPase Activity of Human ATP-binding Cassette Transporter-2 (ABCA2). *In Vivo*, 19: 657-660, 2005.
 129. Townsend, D.M., Findlay, V.J., Fazilev, F., Ogle, M., Fraser, J., Saavedra, J.E., Keefer, L.K. and **Tew, K.D.** A Glutathione S-Transferase π Activated Pro-drug Causes Kinase Activation Concurrent with S-glutathionylation of Proteins. *Molecular Pharmacology*, 69: 501-508, 2006.
 130. Findlay, V.J., Townsend, D.M., Morris, T.E., Fraser, J. P. and **Tew, K.D.** A novel role for human sulfiredoxin in the reversal of glutathionylation. *Cancer Research*, 66:6800-6806, 2006.
 131. Saavedra, J.E., Srinivisan, A., Buzard, G. S., Davies, K. M., Waterhouse, D. J., Inami, K., Wilde, T.C., Citro, M.L., Cuellar, M., Deschamps, J.R., Parrish, D., Shami, P.J., Findlay, V.J., Townsend, D.M., **Tew, K.D.**, Singh, S., Jia, L., Ji, X. and Keefer, L.K. PABA/NO as an Anticancer Lead: Analogue Synthesis, Structure Revision, Solution Chemistry, Reactivity toward Glutathione, and In Vitro Activity. *Journal of Medicinal Chemistry*, 49: 1157-1164, 2006.
 132. Mack, J., Beljanski V., Soulika A., Townsend D.M., Brown C.A., Davis W. Jr., and **Tew, K.D.** 'Skittish' ABCA2 knockout mice display tremor, hyperactivity and abnormal myelin ultrastructure in the CNS. *Molecular and Cellular Biology* 27: 44-53, 2007.

133. Townsend D.M., He, L., Hutchens, S., Pazoles C.J. and **Tew, K.D.** Glutathione S-Transferase P as a Catalyst in Cellular S-Glutathionylation Reactions. *J. Biol. Chem.* 284: 436-445, 2009.
134. Townsend, D.M., Manevich, Y., He, L., Lei, K., Hutchens, S., VandenBerg, T., Pazoles, C.J. and **Tew, K.D.** NOV-002, a glutathione disulfide mimetic as a modulator of cellular redox balance. *Cancer Research*, 68: 2870-2877, 2008.
135. Lei, K., Townsend, D.M. and **Tew, K.D.** Protein cysteine sulfinic acid reductase Sulfiredoxin (Srx) regulates tumor cell growth and drug sensitivity. *Oncogene*, 27: 4877-4887, 2008.
136. Townsend, D.M., **Tew, K.D.**, He, L., King, J.B. and Hanigan, M.H. Role of Glutathione S-Transferase Pi in Cisplatin Induced Nephrotoxicity. *Biomedicine and Pharmacotherapy*, 63: 79-85, 2009.
137. Townsend, D.M., Manevich, Y., He, L., Hutchens, S. and **Tew, K.D.** Nitrosative-stress induced S-glutathionylation of PDI leads to activation of the unfolded protein response. Submitted 2009.
138. Manevich, Y., Townsend, D. M., Hutchens, S. and **Tew, K.D.** Drug induced increases in intracellular calcium result in eNOS catalyzed generation of nitric oxide. Submitted 2009.
139. Townsend, D.M., Manevich, Y., He, L., Chen, Y., Garret, T.E. Pazoles, C.J. and **Tew K.D.** Preclinical Pharmacokinetics and Plasma Biomarker Analysis of NOV-002, a Glutathione Disulfide Mimetic. Submitted 2009.

Books Authored:

1. Preclinical and Clinical Modulation of Anticancer Drugs, by **K.D. Tew**, J.A. Houghton and P.J. Houghton, CRC Press, Boca Raton, 1993.

Books Edited:

1. Mechanisms of Drug Resistance in Neoplastic Cells, edited by P.V. Woolley and **K.D. Tew**, Academic Press, New York, 1988.
2. Structure and Function of Glutathione transferases, edited by **K.D. Tew**, C.B. Pickett, T.J. Mantle, B. Mannervik and J. Hayes, CRC Press, Boca Raton, 1993.
3. Proceedings of the International Conference on Glutathione and Glutathione Linked Enzymes in Human Cancer and Other Diseases, Volumes 111-112, edited by F. Ali-Osman, **K.D. Tew**, and R. Strange, Elsevier Science, New York, 1998.
4. Basic Science of Cancer, edited by G.D. Kruh and **K.D. Tew**, Current Medicine, Philadelphia, 2000.
5. Cancer Section: Redox and Cancer Drugs. In: Current Opinions in Pharmacology. Edited by **K.D. Tew** and F. Ali-Osman. Elsevier, 7 (4) pp353-354, 2007.

Editorials, Reviews, Chapters:

1. Smulson, M., Sudhakar, S., **Tew, K.D.**, Butt, T.R. and Jump, D.B. The Influence of Nitrosoureas on Chromatin Nucleosomal Structure and Function. *In: Effects of Drugs on the Cell Nucleus*, Academic Press, New York, pp. 333-357, 1979.
2. **Tew, K.D.**, Smulson, M.E. and Schein, P.S. Perspectives on the Mode of Action of Nitrosourea Anticancer Agents. *Human Cancer. Its Characterization and Treatment. Excerpta Medica*, Vol. 5, pp. 332-341, 1980.
3. **Tew, K.D.**, Pinsky, S.D., Schein, P.S., Smulson, M.E. and Woolley, P.V. Molecular Aspects of Nitrosamide Carcinogenicity. *Human Cancer. Its Characterization and Treatment. Excerpta Medica*, Vol. 5, pp. 387-395, 1980.
4. **Tew, K.D.**, Smulson, M.E., and Schein, P.S. Molecular Pharmacology of Nitrosoureas. *In: Recent Results in Cancer Research. Carter, Sakurai and Umezawa, editors*, 76:130-140, 1981.

5. **Tew, K.D.** Chromatin and associated nuclear components as potential drug targets. In: Nitrosoureas: Current Status and New Developments. Prestayko, Crooke, Baker, Carter and Schein, editors. Academic Press, New York, pp. 107-121, 1981.
6. **Tew, K.D.** A Molecular Rationale for Nitrosourea Induced Cytotoxicity. In: Nitrosoureas in Cancer Treatment. Serrou, Schein and Imbach, editors. Elsevier, North Holland, pp. 61-78, 1981.
7. Wang, A.L., **Tew, K.D.**, Byrne, P.J. and Schein, P.S. Biochemical and pharmacological properties of nitrosoureas. *Cancer Treat. Rep.* 65:119-123, 1981.
8. **Tew, K.D.** The Interaction of Nuclear Reactant Drugs With Structural Macromolecules of the Nucleus. In: The Nuclear Envelope and Nuclear Matrix. G. Maul, editor. Alan R. Liss, Inc., New York, pp. 279-292, 1982.
9. Vu, V.T., **Tew, K.D.**, Ahlgren, J.D., Byrne, P.J., Wang, A.L., Green, D. and Schein, P.S. Chloroethylnitrosourea interaction with chromatin: A potential mechanism for bone marrow sparing effect of glucose analogs. *Cancer Treat. Symposia* 1:37-46, 1983.
10. Goldin, A., Woolley, P.V., **Tew, K.D.**, and Schein, P.S. Sources of Agents and Their Selection for Antitumor Activity Screening. *Methods and Findings in Experimental and Clinical Pharmacology*, pp. 9-25, 1983.
11. **Tew, K.D.** The mechanism of action of estramustine. *Sem. in Oncol.* 10:21-26, 1983.
12. **Tew, K.D.** and Schein, P.S. Drug resistance and Nitrosoureas. In: Antitumor Drug Resistance. Handbook of Experimental Pharmacology, Vol. 5. Fox, B.W. and Fox, M., editors. Springer-Verlag, W. Germany, pp. 425-442, 1984.
13. Schein, P.S., **Tew, K.D.** and Mathe, G. Pharmacology of Nitrosourea Anticancer Agents. *Clinical Chemotherapy*, pp. 264-274, 1984.
14. **Tew, K.D.** Nuclear Structure and Mechanisms of Drug Resistance. Proceedings of the Second World Conference on Clinical Pharmacology and Experimental Therapeutics. Lemberger, L. and Reidenberg, M.M., editors. pp. 984-994, 1984.
15. **Tew, K.D.** Influence of the Nuclear Matrix on Nuclear Structure and Response to Anticancer Drugs. In: Cancer Chemotherapy and Selective Drug Development. Harrap, K.R., Davis, W. and Calvert, A.H., editors. Martinus Nijhoff, Boston, pp. 419-424, 1984.
16. Busch, H., **Tew, K.D.**, and Schein, P. Molecular and Cell Biology of Cancer. In: Medical Oncology. Basic Principles and Clinical Management of Cancer. Calabresi, P., Schein, P. and Rosenberg, S., editors. Macmillan, New York, pp. 3-40, 1985.
17. Clapper, M.L., Buller, A.L., Smith, T.M. and **Tew, K.D.** Glutathione-S-Transferases in Alkylating Agent Resistant Cells. In: Glutathione S-Transferases and Carcinogenesis. Mantle, T.J., Hayes, J.D. and Pickett, C.B., editors. Taylor & Francis, Philadelphia, pp. 213-224, 1987.
18. Stearns, M.E. and **Tew, K.D.** Interaction of Estramustine with Microtubule Associated Proteins *In Vitro*. *Ann. New York Acad. Sci.* 507:358-361, 1987.
19. **Tew, K.D.** and Clapper, M.L. Glutathione-S-Transferases and Anticancer Drug Resistance. In: Mechanisms of Drug Resistance in Neoplastic Cells. Woolley, P.V. and **Tew, K.D.**, editors. Academic Press, New York, pp. 141-159, 1988.
20. Clapper, M.L. and **Tew, K.D.** Alkylating Agent Resistance. In: Cancer Treatment and Research. McGuire, W.L. and Ozols, R.F., editors. Kluwer Academic Publishers, Norwell, MA, pp. 125-150, 1989.
21. **Tew, K.D.** Enzyme changes linked to anticancer drug resistance. *Ann. Rep. Med. Chem.* 23:265-274, 1988.
22. **Tew, K.D.** and Clapper, M.L. Glutathione S-transferases in drug resistance. In: Resistance to Antitumor Agents in Laboratory and Clinic. Ghione, E. and Rausa, L., editors. Harwood Academic Press, London, pp. 95-103, 1989.
23. **Tew, K.D.** and Stearns, M.E. Estracyt - a Drug With a Novel Mechanism of Cytotoxicity. In: Resistance to Antitumor Agents in Laboratory and Clinic. Ghione, E. and Rausa, L., editors.

- Harwood Academic Press, London, pp. 212-217, 1989.
24. **Tew, K.D.** and Stearns, M.E. Intracellular Effects of Estramustine (Estracyt/Emcyt). In: Therapeutic Progress in Urological Cancers. Alan R. Liss, Inc., New York, pp. 169-175, 1988.
 25. **Tew, K.D.** and Stearns, M.E. Estramustine - a nitrogen mustard/steroid with antimicrotubule activity. *Pharmacol. Ther.* 43:299-319, 1989.
 26. **Tew, K.D.** The Involvement of Glutathione S-Transferases in Drug Resistance. In: Anticancer Drugs. Tapiero, H., Robert, J. and Lampidis, T., editors. Colloque INSERM/John Libbey, Montrouge, France, pp. 103-112, 1989.
 27. **Tew, K.D.** The Cytostatic and Cytotoxic Mechanism of Action of Estracyt. In: Estracyt. Scientific Edition 3. Janknegt, R.A., editor. Assendelft, Amsterdam, pp. 22-33, 1989.
 28. Clapper, M.L., O'Dwyer, P., and **Tew, K.D.** Sensitization of Tumors to Alkylating Agents Using Inhibitors of Glutathione S-Transferases. In: Glutathione S-Transferase and Drug Resistance. Hayes, J., Pickett, C. and Mantle, T., editors. Taylor and Francis, UK, pp. 451-459, 1990.
 29. **Tew, K.D.**, Schisselbauer, J.C., Clapper, M.L. and Kuzmich, S. Glutathione S-Transferases and Resistance to Alkylating Agents. In: Glutathione S-Transferase and Drug Resistance Hayes, J., Pickett, C. and Mantle, T., editors. Taylor and Francis, UK, pp. 309-318, 1990.
 30. **Tew, K.D.** The role of glutathione S-transferases in anticancer drug resistance. In: Proceedings of the Second Pezcoller Symposium, Resistance to Antitumor Agents. Mihich, E., editor. pp. 109-130, 1990.
 31. Kuzmich, S. and **Tew, K.D.** Detoxification Mechanisms and Tumor Cell Resistance to Anticancer Drugs. *Med. Res. Rev.* 11:85-217, 1991.
 32. Sheridan, V.R. and **Tew, K.D.** Mechanism Based Chemotherapy for Prostate Cancer. In: Cancer Surveys, vol. 11, *Prostate Cancer*. Isaacs, J., editor. Cold Spring Harbor Press, New York, pp. 239-254, 1991.
 33. Speicher, L.A. and **Tew, K.D.** Fluorescent probes in antimicrotubule drug activity. *J. Cellular Pharmacol.* 3:51-58, 1992.
 34. Speicher, L.A. and **Tew, K.D.** The Cytoskeleton As a Chemotherapeutic Target. In: Cancer Chemotherapy. Hickman, J.A. and Tritton, T., editors. Blackwell Scientific Publications, Ltd., Oxford, England, pp. 58-106, 1992.
 35. **Tew, K.D.**, Glusker, J.P., Hartley-Asp, B., Hudes, G. and Speicher, L.A. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. *Pharmacol. Ther.* 56:323-339, 1992.
 36. Ciaccio, P.J. and **Tew, K.D.** Glutathione S-Transferases. In: Drug Resistance in Oncology. Teicher, B., editor. Marcel Dekker, Inc., New York, pp. 351-374, 1993.
 37. **Tew, K.D.**, Ciaccio, P.J. and Ranganathan, S. Glutathione S-Transferases As Determinants of Cellular Response to Drugs. In: Mechanism and New Approach to Drug Resistance of Cancer Cells, Elsevier, pp. 147-156, 1993.
 38. Ranganathan, S., Ciaccio, P.J. and **Tew, K.D.** Principles of Drug Modulation Applied to Glutathione S-Transferases. In: Structure and Function of Glutathione Transferases. **Tew, K.D.**, Pickett, C.B., Mantle, T.J., Mannervik, B. and Hayes, J. editors. CRC Press, Boca Raton, pp. 249-256, 1993.
 39. **Tew, K.D.**, Sheridan, V.R. and Speicher, L.A. Determinant factors in estramustine cytotoxicity and resistance. *Cellular Pharmacol.* 1 (Suppl. 1):S53-S58, 1993.
 40. Kuzmich, S. and **Tew, K.D.** Metabolism of Drugs as a Basis for Drug Resistance. *Pharmacology and Therapeutics*. In: Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents. Powis, G., editor. Pergamon Press, Oxford England, pp. 481-497, 1994.
 41. **Tew, K.D.** Glutathione associated enzymes in anticancer drug resistance. *Perspectives in Cancer Research*. *Cancer Res.* 54:4313-4320, 1994.
 42. O'Dwyer, P.J., Hamilton, T.C., Yao, K., **Tew, K.D.** and Ozols, R.F. Modulation of Glutathione and Related Enzymes in Reversal of Resistance to Anticancer Drugs. In: Drug Resistance in Clinical Oncology and Hematology. Fisher, G.A. and Sikic, B.I., editors. pp. 383-396, 1995.

43. Schroder, C.P., Godwin, A.K., O'Dwyer, P.J., **Tew, K.D.**, Hamilton, T.C. and Ozols, R.F. Glutathione and Drug Resistance. *Cancer Invest.* 14:58-168, 1996.
44. **Tew, K.D.**, Colvin, O.M. and Chabner, B.A. Alkylating Agents. *In: Cancer: Chemotherapy and Biotherapy: Principles and Practice.* Chabner, B.A. and Longo, D.L., editors. Lippincott-Raven, Philadelphia, pp. 297-332, 1996.
45. Laing, N. and **Tew, K.D.** Drug Resistance to Chemotherapy - Mechanisms. *In: Encyclopedia of Cancer.* Bertino, J.R., editor. Academic Press, New York, pp. 560-570, 1996.
46. Ciaccio, P.J., Shen, H. and **Tew, K.D.** Effects of glutathione S-transferase inhibitors on detoxification gene expression. *International Workshop of Glutathione S-Transferases.* Vermeulen, P., editor. Taylor and Francis, London, pp. 213-226, 1996.
47. Raha, A. and **Tew, K.D.** Glutathione S-transferases in anticancer drug response. *In: Advances in Cancer Research.* Hait, W., editor, pp. 83-122, 1996.
48. Barone, L.R. and **Tew, K.D.** Glutathione and Glutathione Associated Enzymes in Multidrug Resistance. *In: Multidrug Resistance in Cancer Cells.* Gupta, S. and Tsuruo, T., editors. John Wiley and Sons, Chichester, England, pp. 151-176, 1996.
49. Ciaccio, P.J. and **Tew, K.D.** Adaptive response to glutathione S-transferase inhibitors. *Br. J. Cancer* 74:S93-S98, 1996.
50. Helt, A., Kruh, G. and **Tew, K.D.** The use of fluorescent probes in characterizing drug resistance in cultured cells. *In: The Analytical Use of Fluorescent Probes in Cancer Research.* NATO Advanced Research Workshop. Kohen, E., editor. Plenum Press, New York, pp. 339-348, 1996.
51. **Tew, K.D.** Genetic polymorphisms of detoxification enzymes. *Cellular Pharmacol.* 3:143-152, 1996.
52. O'Brien, M. and **Tew, K.D.** Glutathione and related enzymes in multidrug resistance. *Eur. J. Cancer* 32:967-978, 1996.
53. **Tew, K.D.** and Speicher, L.A. Modulation and Circumvention of Drug Resistance. *In: Molecular Genetics of Drug Resistance.* Hayes J.D. and Wolf, R., editors. Harwood Academic Publishers, Switzerland, pp. 373-403, 1997.
54. **Tew, K.D.**, Dutta, S. and Schultz, M. Inhibitors of glutathione S-transferases as therapeutic agents. *Adv. Drug Delivery Rev.* 26:91-104, 1997.
55. Speicher, L.A. and **Tew, K.D.** Determinants of Estramustine Resistance. *In: Drug Resistance in Oncology.* Bernal, editor. Marcel Dekker, New York, pp. 279-294, 1997.
56. Shen, H., Kauvar, L. and **Tew, K.D.** Importance of glutathione and associated enzymes in drug response. *Oncol. Res.* 9:295-302, 1997.
57. **Tew, K.D.**, O'Brien, M., Laing, N.M. and Shen, H. Co-ordinate changes in the expression of protective genes in drug resistant cells. *In: International Conference on Glutathione and Glutathione-Linked Enzymes in Human Cancer and Other Diseases.* Ali-Osman, F., Strange, L. and **Tew, K.D.**, editors. Elsevier, New York. *Chem Biol. Interact.* 111:199-212, 1998.
58. Laing, N.M., Ranganathan, S., Shen, H., Kauvar, L. and **Tew, K.D.** Coordinate Expression of Drug Resistance Genes. *In: Progress in Cancer Therapy, Volume II.* Hortobagyi, G. and Khayat, D., editors. Blackwell Science, Massachusetts, pp. 145-158, 1999.
59. **Tew, K.D.** Oxidants and antioxidants: outcome of prevention and treatment strategies. *Guest Editorial, Biomed. and Pharmacother.* 53:167-168, 1999.
60. Gaté, L., Paul, J., Nguyen, B.A., **Tew, K.D.** and Tapiero, H. Oxidative stress induced pathologies: role of antioxidants. *Biomed. and Pharmacother.* 53:169-180, 1999.
61. Adler, V., Yin, Z., **Tew, K.D.** and Ronai, Z. Role of redox potential in stress signalling. *Oncogene.* 18:6104-6111, 1999.
62. **Tew, K.D.** and Ronai, Z. GST function in drug and stress response. *Drug Res. Updates* 2:143-147, 1999.
63. Ruscoe, J., O'Brien, M.L., Freer, S., Shen, H., Rosario, L., Vulevic, B. and **Tew, K.D.** Co-ordinate expression of detoxification genes in drug resistance. *Clin. Chem. Enzymol. Commun.* 8:403-416,

- 2000.
64. **Tew, K.D.** Is there a role for glyoxalase I inhibitors as antitumor drugs? *Drug Resistance Updates* 3:263-264, 2000.
 65. Kruger, W.D. and **Tew, K.D.** Pharmacogenetics and Cancer. *In: Basic Science of Cancer.* Kruh, G.D. and **Tew, K.D.**, editors. Current Medicine, Philadelphia, pp. 257-270, 2000.
 66. Davis, W., Jr., Ronai, Z. and **Tew, K.D.** Cellular thiols and reactive oxygen species in drug-induced apoptosis. *J. Pharmacol. Exper. Ther. (Perspectives in Pharmacology)* 296:16, 2001.
 67. **Tew, K.D.** The influence of GST-targeted drugs on cell proliferation and stress response. *Chem. Biol. Interact.* 133:295-300, 2001.
 68. Gaté, L. and **Tew, K.D.** Glutathione S-transferases as emerging therapeutic targets. *Expert Opin. Ther. Targets* 5:477-489, 2001.
 69. Tapiero, H., **Tew, K.D.**, Gaté, L. and Machover, D. Prevention of pathologies associated with oxidative stress and dietary intake deficiencies: folate deficiency and requirements. *Biomed. Pharmacother.* 201:55:381-390, 2001.
 70. Tapiero, Gaté, L. and **Tew, K.D.** Iron: deficiencies and requirements. *Biomed. Pharmacother.* 55:324-332, 2001.
 71. Golemis, E.A., **Tew, K.D.** and Dadke, D. Protein interaction-targeted drug discovery: evaluating critical issues. *Biotechniques* 32:636-647, 2002.
 72. Davis, W., Chen, Z. J., Ile, K.E. and **Tew, K.D.** ABCA2 transporter. *In: Alliance for Cellular Signaling. Website and Nature Publishers, 2002.*
 73. Townsend, D. M., Gaté, L., Findlay, V. and **Tew, K.D.** Glutathione S-Transferase P1-1. *In: Alliance for Cellular Signaling. Website and Nature Publishers, 2002.*
 74. Townsend, D.M. and **Tew, K.D.** The Role of Glutathione S-Transferases in Drug Resistance. *Oncogene* 22: 7369-7375, 2003.
 75. Tapiero, H., Ba G.N., Couvreur, P. and **Tew, K.D.** Polyunsaturated fatty acids (PUFA) and eicosanoids n human health and pathologies. *Biomed. Pharmacother.* 56(5): 215-22, 2002.
 76. Tapiero H., **Tew, K.D.**, Ba, G.N. and Mathé, G. Polyphenols: do they play a role in the prevention of human pathologies? *Biomed. Pharmacother.*, 56(4): 200-207, 2002.
 77. Tapiero H., Ba, G.N., and **Tew, K.D.** Estrogens and environmental estrogens. *Biomed, Pharmacother.* 56(1): 36-44, 2002.
 78. Chen Z. J., Gaté L., Davis W. Jr., Ile K. E. and **Tew, K. D.** Integration of Amplified Differential Gene Expression (ADGE) and DNA microarray. *IUBMB Life*, 54 (6): 335-338, 2002.
 79. Chen Z. J., Davis W. Jr., Gate L. and Tew K. D. Amplified differential gene expression (ADGE), in *Analyzing Gene Expression*, eds. Lorkowski and Cullen, published by Wiley-VCH, 2003.
 80. Tapiero H., Mathé G., Couvreur P., **Tew, K.D.** I. Arginine. *Biomed. Pharmacother.*, 56(9):439-445, 2002.
 81. Tapiero H., Mathé G., Couvreur P., **Tew, K.D.** II. Glutamine and glutamate. *Biomed. Pharmacother.*, 56(9):446-457, 2002.
 82. Chen Z.J. and **Tew, K.D.** Amplified Differential Gene Expression Microarray. *In : Gene Expression Profiling: Methods and Protocols.* Ed. Shimkets RA, Humana Press Vol 258: 95-106, 2004.
 83. Townsend D.M., **Tew, K.D.**, Tapiero H. The importance of glutathione in human disease. *Biomed Pharmacother.*, 57(3):145-55, 2003.
 84. Tapiero H, Townsend DM, **Tew, KD.** The antioxidant role of selenium and seleno-compounds. *Biomed Pharmacother.* 57(3):134-44, 2003.
 85. Townsend D.M. and **Tew, K.D.** Cancer drugs, genetic variation and the glutathione S-transferase gene family. *American Journal of Pharmacogenomics*, 3: 157-172, 2003.
 86. Tapiero H., Townsend D.M. and **Tew, K.D.** Phytosterols in the prevention of human pathologies. *Biomed. Pharmacother.* 57: 321-325, 2003.
 87. Tapiero H. and **Tew, K.D.** Trace elements in human physiology and pathology: zinc and

- metallothioneins. *Biomed. Pharmacother.* 57(9): 399-411, 2003.
88. Townsend D.M., Tapiero H. and **Tew, K.D.** Sulfur containing amino acids in human disease. *Biomed. Pharmacother.* 58: 47-55, 2004.
 89. Tapiero, H., Townsend, D.M. and **Tew, K.D.** Trace elements in human physiology and pathology. Copper. *Biomed Pharmacother.* 57(9):386-98, 2003.
 90. Gaté L. and **Tew, K.D.** Alkylating Agents. In :- *Cancer Management in Man* Vol. 10 CGAP series. Ed. Minev B. Kluwer Academic Publishers, Dordrecht, The Netherlands. In press, 2004.
 91. **Tew, K.D.** Small molecule inhibition of hypoxia inducible factor-1* – a viable therapeutic approach? *Molecular Cancer Therapeutics (Commentary)*, 3: 245-246, 2004.
 92. Tapiero, H, Townsend, D.M. and **Tew, K.D.** The role of carotenoids in the prevention of human pathologies. *Biomed. Pharmacother.* 58:100-110, 2004.
 93. **Tew, K.D.**, Boyd, J.T., Chen, Z.J., Davis, W., Fazilev, F. Findlay, V., Gaté, L., Ile, K.E., Soulika, A. and Townsend, D.M. Glutathione and ABC transporters as determinants of sensitivity to oxidative and nitrosative stress. *Journal of Nutrition*, 134: 3205s-3206s, 2004.
 94. Tapiero, H., Townsend, D.M. and **Tew, K.D.** Organosulfur compounds from alliaceae in the prevention of human pathologies. *Biomed. Pharmacother.* 58: 183-193, 2004.
 95. Findlay, V.J., Townsend, D.M. and **Tew, K.D.** Glutathione and glutathione S-transferases in drug resistance. In *Cancer Drug Discovery & Development: Cancer Drug Resistance*. Ed. Teicher, B. pp2313-222, 2006.
 96. Townsend D.M., Findlay, V.L. and **Tew, K.D.** Glutathione S-Transferases as regulators of kinase pathways and anticancer drug targets. In: *Methods in Enzymology Series: Conjugation Enzymes*. Edited by H. Sies and L. Packer, Elsevier, New York. Volume 401, 286-306, 2005.
 97. Findlay, V.J., Townsend, D.M. and **Tew, K.D.** Glutathione and Glutathione S-Transferases as Targets for Anticancer Drug Development. In: *Toxicology of Glutathione S-Transferases*. Ed. Awasthi, Y. Taylor and Francis Books, Inc., Boca Raton, FL. pp155-178, 2006.
 98. **Tew, K.D.**, O.M. Colvin and Jones, R.B. Chapter 12: Clinical and High Dose Alkylating Agents. In: *Cancer: Chemotherapy and Biotherapy: Principles and Practice*. Chabner, B.A. and Longo, D.L., editors. Lippincott-Raven, Philadelphia, pp. 283-309, 2005.
 99. **Tew, K.D.** TLK-286: a novel glutathione S-transferase-activated prodrug. *Expert Opin Investig Drugs*. 14(8): 1047-54, 2005.
 100. Townsend, D.M., Tucker, J, Beljanski, V. and **Tew, K.D.** Human ATP Binding Casette transporter A2. In *Alliance for Cellular Signalling*. Website and Nature Publishers, 2005.
 101. Fraser, J., Townsend D.M. and Tew, K.D. Human glutathione S-transferase P1. In: *Alliance for Cellular Signaling*. Website and Nature Publishers, 2005.
 102. Ogle, M., Townsend, D.M. and **Tew, K.D.** Human glutathione S-transferase P1. In: *Alliance for Cellular Signaling*. Website and Nature Publishers, 2005.
 103. McIlwain, C.C., Townsend, D.M. and **Tew, K.D.** Glutathione S-Transferase Polymorphisms and Cancer Incidence and Therapy. *Oncogene*, 25: 1639-1648, 2006.
 104. **Tew, K.D.** Redox in Redux: Emergent Roles for Glutathione S-Transferase P (GSTP) in Regulation of Cell Signaling and S-glutathionylation. *Biochemical Pharmacology Commentary*; 73: 1257-1269, 2007.
 105. Mack, J.T, Beljanski, V, **Tew, K.D.** and Townsend, D.M. The ATP-binding cassette transporter ABCA2 as a mediator of intracellular trafficking. *Biomed and Pharmacotherapy*, 60:587-592, 2006.
 106. **Tew, K.D.** How is a conservative US administration influencing NCI funding? *Editorial Biomedicine and Pharmacotherapy* 60: 500-501, 2006.
 107. Mack, J.T., Townsend, D.M., Beljanski, V. and **Tew, K.D.** The ABCA2 transporter: Intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. *Current Drug Metabolism*, Bentham Press. 8: 47-57, 2007.
 108. **Tew, K.D.** Alkylating Agents. In *Cancer: Principles and Practice of Oncology* 8th Edition. Editors DeVita, V.T., Lawrence, T.S. and Rosenberg S.A. Lippincott, Williams and Wilkins, pp 407-418, 2008.

109. Chen, Z.J. and **Tew, K.D.** ADGE-Micoarray. In DNA Microarrays – Methods Express. Ed Schena, M. Scion Life Sciences Publishers, Woodbury, NY, pp21-30, 2007.
110. Townsend, D.M., Pazoles,C.J. and **Tew, K.D.** NOV-002 a mimetic of oxidized glutathione. In: Expert Opinion on Investigational Drugs 17: 1075-1083, 2008.
111. Mack, J.T., Brown, C.B. and **Tew, K.D.** ABCA2 as a therapeutic target in cancer and nervous system disorders. In: Expert Opinion on Drug Targets. 12: 491-504, 2008.
112. Townsend, D.M., Tapiero, H. and **Tew, K.D.** Human Pathologies and Aberrant Sulfur Metabolism. In: Reference Book on Glutathione and Sulfur Amino Acids in Human Health and Disease. Edited by Masella R. and Mazza G. John Wiley and Sons. Chapter 14: pages 317-342, 2009.
113. Townsend, D.M. and **Tew, K.D.** Pharmacology of a mimetic of glutathione disulfide, NOV-002. Biomedicine and Pharmacotherapy, 63: 75-78 2009.